Target intelligence / Profile preview

NAD\(^+\)-consuming enzyme

Molecular classification
Enzyme, Hydrolase, Transferase
01

Overview

NAD\(^+\)-consuming enzymes are a broad family of proteins that utilize nicotinamide adenine dinucleotide (NAD\(^+\)) as a substrate or cofactor in various cellular processes such as DNA repair, post-translational protein modification, and signaling[1][2][3][5][6][8]. Key families include sirtuins (deacetylases controlling epigenetic and metabolic regulation), poly(ADP-ribose) polymerases (PARPs; involved in DNA repair and cell stress responses), and cyclic ADP-ribose synthases (e.g., CD38, important in immune modulation and calcium signaling)[1][3][5][6][8]. More recently, the neuronal protein SARM1, which cleaves NAD\(^+\) and is involved in axonal degeneration, has been added to this group[6][8]. These enzymes are implicated in aging, cancer, inflammation, metabolic, and neurodegenerative diseases. They are clinically significant as both disease markers and therapeutic targets, notably in oncology and autoimmune indications, with several targeted small molecules and monoclonal antibodies approved or in clinical development[5][8].

Other names
NAD\(^+\)-utilizing enzymeNAD\(^+\) hydrolase familyNAD-dependent enzyme
02

Mechanism of action

Enzymatic inhibition (competitive, allosteric, or substrate-based); Blockade of NAD\(^+\) binding site; Modulation of gene expression via epigenetic effects; Disruption of protein-protein interactions

03

Biological functions

DNA repairEpigenetic regulation/modificationSignal transductionCell death (apoptosis, necrosis)Immune responseEnergy metabolism regulationGenomic stability maintenanceCell cycle regulationCircadian rhythm modulation
04

Disease associations

CancerNeurodegenerative diseaseCardiovascular diseaseInflammationAging-related diseasesMetabolic disorders
05

Safety considerations

Disruption of NAD\(^+\) homeostasis (risk of cytotoxicity, metabolic syndrome)Hematological toxicity (for CD38-targeting drugs)Off-target effects on DNA repair or cell survivalImmunosuppression (antibody-based drugs)Potential neurotoxicity (SARM1 inhibitors)
06

Interacting drugs

PARP inhibitors (e.g., olaparib, niraparib)

3 more in the full profile.

07

Biomarkers

NAD\(^+\) and NADH levels (tissue or plasma)Activity or phosphorylation of target proteins (e.g., poly-ADP-ribosylation for PARPs)Sirtuin or PARP expression levelsChanges in acylation or ribosylation marks on protein substrates

Beyond the preview

Go deeper on NAD\(^+\)-consuming enzyme.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAD\(^+\)-consuming enzyme.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call